Article

A Molecular‐Targeting Photosensitizer to Inhibit DNA Damage Repair System and Induce cGAS‐STING Pathway Activation for Photo‐Immunotherapy of Ovarian Cancer

2024-11-26

Abstract excerpt

Abstract Poly(ADP‐ribose) polymerase (PARP) inhibitors are commonly utilized in the clinical management of patients with platinum‐sensitive recurrent and late‐stage ovarian cancer, which constitutes a significant proportion of gynecological cancer‐related mortality. Nonetheless, the constraints of their monofunctional properties and limited therapeutic efficacy observed in advanced cancer cases necessitate the exp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ccb66cd6-8ad1-5d4b-966b-3e0b659a4582
DOI: 10.1002/adfm.202415087

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Molecular‐Targeting Photosensitizer to Inhibit DNA Damage Repair System and Induce cGAS‐STING Pathway Activation for Photo‐Immunotherapy of Ovarian CancerDOI 10.1002/adfm.202415087Read

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer TherapySemantic proximity Read

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translationSemantic proximity Read

The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.Semantic proximity Read

Photodynamic Therapy and Tumor Microenvironment-Targeting Strategies: A Novel Synergy at the Frontier of Cancer TreatmentSemantic proximity Read

Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.Semantic proximity Read

Auranofin induces lethality driven by reactive oxygen species in high-grade serous ovarian cancer cellsSemantic proximity Read

Breaking the Iron Homeostasis: A “Trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP InhibitionSemantic proximity Read

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor ResponseSemantic proximity Read

Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistanceSemantic proximity Read

Fresh Platinum Complexes with Promising Antitumor ActivitySemantic proximity Read

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian CancerSemantic proximity Read

Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication ArrestSemantic proximity Read